In a significant development, two top executives at Kobayashi Pharmaceutical, a renowned Japanese drugmaker, have resigned amidst an ongoing investigation into the deaths of 80 individuals potentially linked to the company’s products. The president, Akihiro Kobayashi, and chairman, Kazumasa Kobayashi, both from the founding family, stepped down to “clarify executive responsibility” over the crisis involving their beni kōji fermented rice products.
Kobayashi Pharmaceutical initiated a recall of five of its products in March after receiving reports of kidney problems from customers. The company began its investigation in January following a doctor’s alert about health issues. Symptoms reported by affected customers included urine discoloration, limb swelling, and fatigue. The probe revealed a potentially toxic acid produced by mould at one of the company’s factories as a possible cause.
The company has opened a hotline for customers seeking advice and has expressed deep apologies. In a statement, the board of directors said they “pray for those who died and offer condolences to the bereaved families,” and reiterated their apology to customers and business partners.
Satoshi Yamane, the head of sustainability policy, will take over as the new president. Akihiro Kobayashi will remain with the company to handle compensation arrangements, taking responsibility for the harm caused.
Beni kōji, rice fermented with monascus purpureus—a reddish-purple mould species— is marketed as a health supplement for high cholesterol and blood pressure and is also used traditionally as a food dye.
For more information and updates on this ongoing situation, follow our coverage on the Kobayashi Pharmaceutical investigation and executive changes.
